"Although many pharmaceutical companies have launched therapeutic drugs for COVID-19, Pfizer’s Paxlovid takes the top spot as market leader. The drug has expected peak sales of $30.7 billion in 2022 and total generated sales of $81 billion between 2021 and 2028, according to GlobalData, a leading data and analytics company."
So..... if Enanta's compound were better, more efficacious, once a day without boosting it would seem approval would be simple since the bar is so incredibly low.